Ascendis Pharma Net Income From Continuing Ops Over Time
| ASND Stock | USD 239.14 0.08 0.03% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Ascendis Pharma Performance and Ascendis Pharma Correlation. Will Biotechnology sector continue expanding? Could Ascendis diversify its offerings? Factors like these will boost the valuation of Ascendis Pharma. If investors know Ascendis will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Ascendis Pharma data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (4.43) | Revenue Per Share | Quarterly Revenue Growth 0.423 | Return On Assets | Return On Equity |
Understanding Ascendis Pharma AS requires distinguishing between market price and book value, where the latter reflects Ascendis's accounting equity. The concept of intrinsic value - what Ascendis Pharma's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Ascendis Pharma's price substantially above or below its fundamental value.
Understanding that Ascendis Pharma's value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Ascendis Pharma represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. In contrast, Ascendis Pharma's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Cross Equities Net Income From Continuing Ops Analysis
Compare Ascendis Pharma AS and related stocks such as Ionis Pharmaceuticals, BridgeBio Pharma, and Revolution Medicines Net Income From Continuing Ops Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| IONS | (61.3 M) | (84.8 M) | (65.5 M) | (60.6 M) | (39 M) | (88.3 M) | (86.6 M) | (17.3 M) | 215 M | 303.3 M | (486.8 M) | (28.6 M) | (269.7 M) | (366.3 M) | (453.9 M) | (408.5 M) | (388.1 M) |
| BBIO | (43.8 M) | (43.8 M) | (43.8 M) | (43.8 M) | (43.8 M) | (43.8 M) | (43.8 M) | (43.8 M) | (169.5 M) | (288.6 M) | (505.5 M) | (586.5 M) | (484.7 M) | (653.3 M) | (543.3 M) | (732.9 M) | (696.3 M) |
| RVMD | (31.1 M) | (31.1 M) | (31.1 M) | (31.1 M) | (31.1 M) | (31.1 M) | (31.1 M) | (31.1 M) | (41.8 M) | (47.7 M) | (108.2 M) | (187.1 M) | (248.7 M) | (436.4 M) | (600.1 M) | (540.1 M) | (513.1 M) |
| ROIV | (900.2 M) | (900.2 M) | (900.2 M) | (900.2 M) | (900.2 M) | (900.2 M) | (900.2 M) | (900.2 M) | (900.2 M) | (900.2 M) | (900.2 M) | (924.1 M) | (1.2 B) | 4.2 B | (729.8 M) | (839.2 M) | (797.3 M) |
| SMMT | (6.1 M) | (6.1 M) | (6.1 M) | (6.1 M) | (17.1 M) | (547 M) | (26.7 M) | (10.1 M) | 9.9 M | (52.7 M) | (52.7 M) | (88.6 M) | (78.8 M) | (614.9 M) | (221.3 M) | (1.1 B) | (1 B) |
| GH | (46.1 M) | (46.1 M) | (46.1 M) | (46.1 M) | (46.1 M) | (46.1 M) | (46.1 M) | (83.2 M) | (84.3 M) | (67.9 M) | (246.3 M) | (384.8 M) | (654.6 M) | (479.4 M) | (436.4 M) | (416.3 M) | (437.1 M) |
| MDGL | (47.4 M) | (47.4 M) | (62.8 M) | (90.2 M) | (86.2 M) | (68.7 M) | (26.4 M) | (31.5 M) | (33 M) | (83.9 M) | (202.3 M) | (242.1 M) | (295.4 M) | (373.6 M) | (465.9 M) | (419.3 M) | (398.3 M) |
| EXEL | 75.7 M | 75.7 M | (147.6 M) | (244.8 M) | (268.5 M) | (169.7 M) | (70.2 M) | 154.2 M | 690.1 M | 321 M | 111.8 M | 231.1 M | 182.3 M | 92.1 M | 521.3 M | 782.6 M | 821.7 M |
| BMRN | 205.8 M | (53.8 M) | (114.3 M) | (176.4 M) | (134 M) | (171.8 M) | (630.2 M) | (117 M) | (77.2 M) | (23.8 M) | 859.1 M | (64.1 M) | 141.6 M | 147 M | 426.9 M | 348.9 M | 366.3 M |
| MRNA | (6.5 M) | (6.5 M) | (6.5 M) | (6.5 M) | (6.5 M) | (1.1 M) | (216.2 M) | (255.9 M) | (384.7 M) | (514 M) | (747.1 M) | 12.2 B | 8.4 B | (3.5 B) | (3.6 B) | (2.8 B) | (2.7 B) |
Ascendis Pharma AS and related stocks such as Ionis Pharmaceuticals, BridgeBio Pharma, and Revolution Medicines Net Income From Continuing Ops description
My Equities
My Current Equities and Potential Positions
| Ascendis Pharma AS | ASND |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | Tuborg Boulevard 12, |
| Exchange | NASDAQ Exchange |
USD 239.14
Check out Ascendis Pharma Performance and Ascendis Pharma Correlation. You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.
Ascendis Pharma technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.